Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 497Neoplasms 302Breast Neoplasms 294Colorectal Neoplasms 228Neoplasm Metastasis 194Prostatic Neoplasms 175Ovarian Neoplasms 173Lung Neoplasms 159Multiple Myeloma 158Recurrence 131Melanoma 125Pancreatic Neoplasms 115Squamous Cell Carcinoma of Head and Neck 104Stomach Neoplasms 102Leukemia, Myeloid, Acute 101Endometrial Neoplasms 101Small Cell Lung Carcinoma 88Leukemia, Lymphocytic, Chronic, B-Cell 87Triple Negative Breast Neoplasms 84Lymphoma, Non-Hodgkin 84Carcinoma, Renal Cell 83Carcinoma, Hepatocellular 79Urinary Bladder Neoplasms 77Lymphoma, Large B-Cell, Diffuse 74Lymphoma, Follicular 68Advanced Solid Tumors 66Lymphoma 62Parkinson Disease 4, Autosomal Dominant Lewy Body 61Glioblastoma 58Head and Neck Neoplasms 56

Interventions

Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Platinum-resistant Recurrent Ovarian Cancer × 90 days × Clear all
NCT06434610 2026-05-05

A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.

Shanghai Jiaolian Drug Research and Development Co., Ltd

Phase 2 Recruiting
90 enrolled
Gynecologic

Platinum-resistant Recurrent Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡